Lymphoma Tumor Homograft Models

Lymphomas comprise a number of diseases with different histopathological features. In recent years the main molecular drivers for the various lymphoma subtypes have been identified, leading to the identification of potential targets for therapeutic applications. To progress novel agents targeting lymphoma, relevant preclinical models are required. Our lymphoma tumor homografts have been developed by trasplantation of GEMM tumors into syngeneic hosts, preserving original tumor histo- and molecular pathology and driver mutations, including KRAS and MYC activation or TP53 loss.

MODEL NUMBER ORIGINAL GEMM MUTATION # per page
mLY6014CLICK TO VIEW
mLY6041Kras (G12D); P53-/-CLICK TO VIEW
mLY6043IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6061KRAS (G12D); P53-/-CLICK TO VIEW
mLY6062KRAS (G12D); P53-/-CLICK TO VIEW
mLY6068IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6096IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6097IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6098IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6101IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6102IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6149IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6150IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6166IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6167IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6168IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6169IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6170IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6171IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6172IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6173IgH-Myc TG (Eµ Myc)CLICK TO VIEW
mLY6176Ptch1-/+; P53-/-CLICK TO VIEW
mLY6178Ptch1-/+; P53-/-CLICK TO VIEW
mLY6184Ptch1-/+; P53-/-CLICK TO VIEW
mLY6186Ptch1-/+; P53-/-CLICK TO VIEW
mLY6188Ptch1-/+; P53-/-CLICK TO VIEW
mLY9012Eu-MycCLICK TO VIEW
mLY9022Eu-MycCLICK TO VIEW
mLY9023Eu-MycCLICK TO VIEW